INT10517

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1989
Last Reported 2005
Negated 0
Speculated 0
Reported most in Abstract
Documents 16
Total Number 17
Disease Relevance 8.44
Pain Relevance 3.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Plat) extracellular space (Plat) extracellular region (Plat)
molecular_function (Plat) cytoplasm (Plat)
Anatomy Link Frequency
Coronary artery 1
femoral artery 1
platelet 1
vascular endothelium 1
Plat (Rattus norvegicus)
Pain Link Frequency Relevance Heat
metalloproteinase 12 100.00 Very High Very High Very High
bradykinin 10 99.52 Very High Very High Very High
IPN 25 99.36 Very High Very High Very High
cva 1 92.92 High High
agonist 2 90.08 High High
antagonist 4 87.64 High High
Angina 8 87.28 High High
Pain 3 75.20 Quite High
Percutaneous transluminal coronary angioplasty 2 75.00 Quite High
b2 receptor 1 75.00 Quite High
Disease Link Frequency Relevance Heat
Acute Coronary Syndrome 45 99.68 Very High Very High Very High
Myocardial Infarction 7 99.08 Very High Very High Very High
Thrombosis 10 98.88 Very High Very High Very High
Coronary Artery Disease 22 98.20 Very High Very High Very High
Syndrome 15 96.48 Very High Very High Very High
Disorder Of Lipid Metabolism 2 95.98 Very High Very High Very High
Hemorrhage 1 92.92 High High
Hematoma 2 91.20 High High
Brain Injury 1 89.44 High High
Cv General 3 Under Development 7 87.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Genes such as gelatinase A (MMP2), cathepsin L, tissue inhibitor metalloproteinases 2 (TIMP2) and 3 (TIMP3), plasminogen activator inhibitor1 (PAI1), tissue type plasminogen activator (tPA), urokinase plasminogen activator (uPA), endothelin 1, calponin, carboxypeptidase D and calponin acidic were down regulated.
Localization (tissue) of tissue type plasminogen activator associated with metalloproteinase
1) Confidence 0.47 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC548144 Disease Relevance 0 Pain Relevance 0.05
Genes such as gelatinase A (MMP2), cathepsin L, tissue inhibitor metalloproteinases 2 (TIMP2) and 3 (TIMP3), plasminogen activator inhibitor1 (PAI1), tissue type plasminogen activator (tPA), urokinase plasminogen activator (uPA), endothelin 1, calponin, carboxypeptidase D and calponin acidic were down regulated.
Localization (tissue) of tPA associated with metalloproteinase
2) Confidence 0.47 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC548144 Disease Relevance 0 Pain Relevance 0.05
Because t-PA antigen levels and PAI-1 activity were highest in the morning, the variation in t-PA activity was probably not due to decreased secretion of t-PA but instead to changes in the secretion of PAI-1.
Localization (secretion) of t-PA
3) Confidence 0.35 Published 1989 Journal Circulation Section Abstract Doc Link 2491971 Disease Relevance 0.15 Pain Relevance 0.08
The t-PA release from this semi-IPN hydrogel was examined by measuring the plasmin activity using the chromogenic substrate S-2251.
Localization (release) of t-PA associated with ipn
4) Confidence 0.33 Published 2001 Journal J Control Release Section Abstract Doc Link 11451495 Disease Relevance 0 Pain Relevance 0.35
Aside from the porous structure, other factors including the content of the crosslinker, PLGA and t-PA could all be varied to regulate t-PA release from the hydrogel.
Localization (release) of t-PA
5) Confidence 0.33 Published 2001 Journal J Control Release Section Abstract Doc Link 11451495 Disease Relevance 0 Pain Relevance 0.24
Findings in this paper demonstrated that the porous structure of the hydrogel facilitated t-PA release when compared to the dense structure.
Localization (release) of t-PA
6) Confidence 0.33 Published 2001 Journal J Control Release Section Abstract Doc Link 11451495 Disease Relevance 0 Pain Relevance 0.29
Although resting levels of t-PA antigen were not significantly different from normal during myocardial infarction, the capacity of the vascular endothelium to release t-PA after five minutes of venous occlusion was impaired (p less than 0.01).
Localization (release) of t-PA in vascular endothelium associated with myocardial infarction
7) Confidence 0.32 Published 1992 Journal Aust N Z J Med Section Abstract Doc Link 1497553 Disease Relevance 0.69 Pain Relevance 0.08
These results suggest that a porous PLGA semi-IPN hydrogel could potentially be a useful local delivery system to release active t-PA primarily at the site of a thrombus.
Localization (release) of t-PA associated with ipn and thrombosis
8) Confidence 0.29 Published 2001 Journal J Control Release Section Abstract Doc Link 11451495 Disease Relevance 0.10 Pain Relevance 0.23
Porous structure of hydrogel was essential in this system to yield a large surface area so that t-PA release could be facilitated.
Localization (release) of t-PA
9) Confidence 0.29 Published 2001 Journal J Control Release Section Abstract Doc Link 11451495 Disease Relevance 0.09 Pain Relevance 0.27
After diagnostic coronary angiography, femoral artery endothelial and smooth muscle function were assessed by infusing acetylcholine (ACh) and nitroglycerin (GTN), and tissue-type plasminogen activator (t-PA) release across the femoral circulation was measured as the difference between arterial and venous concentrations before and after ACh and GTN stimulation.
Localization (release) of t-PA in femoral artery
10) Confidence 0.19 Published 2005 Journal Am. J. Physiol. Heart Circ. Physiol. Section Abstract Doc Link 16014611 Disease Relevance 1.05 Pain Relevance 0.12
There were no significant differences between groups in relevant baseline characteristics apart from significantly higher C-reactive protein levels and reduced net t-PA release in the ACS group at baseline (P < 0.05).
Localization (release) of t-PA associated with acute coronary syndrome
11) Confidence 0.19 Published 2005 Journal Am. J. Physiol. Heart Circ. Physiol. Section Abstract Doc Link 16014611 Disease Relevance 1.08 Pain Relevance 0.10
Although baseline t-PA release was impaired in the ACS patients (0.09 +/- 0.06 compared with 0.39 +/- 0.33 and 0.49 +/- 0.56 ng/ml; P = 0.03), stimulation of t-PA release by ACh and GTN occurred only in the control subjects and not in the ACS or SAP patients.
Localization (release) of t-PA associated with acute coronary syndrome
12) Confidence 0.19 Published 2005 Journal Am. J. Physiol. Heart Circ. Physiol. Section Abstract Doc Link 16014611 Disease Relevance 0.85 Pain Relevance 0.05
Coronary artery disease is associated with impaired endothelium-dependent dilatation and impaired stimulation of t-PA release in the systemic circulation.
Localization (release) of t-PA in Coronary artery associated with coronary artery disease
13) Confidence 0.19 Published 2005 Journal Am. J. Physiol. Heart Circ. Physiol. Section Abstract Doc Link 16014611 Disease Relevance 0.65 Pain Relevance 0
Although baseline t-PA release was impaired in the ACS patients (0.09 +/- 0.06 compared with 0.39 +/- 0.33 and 0.49 +/- 0.56 ng/ml; P = 0.03), stimulation of t-PA release by ACh and GTN occurred only in the control subjects and not in the ACS or SAP patients.
Localization (release) of t-PA associated with acute coronary syndrome
14) Confidence 0.17 Published 2005 Journal Am. J. Physiol. Heart Circ. Physiol. Section Abstract Doc Link 16014611 Disease Relevance 0.93 Pain Relevance 0.06
[Intracranial administration of tissue plasminogen activator and its important factors involved concerning the pH and osmotic pressure].
Localization (administration) of tissue plasminogen activator
15) Confidence 0.04 Published 1991 Journal No Shinkei Geka Section Title Doc Link 1944789 Disease Relevance 0.52 Pain Relevance 0.10
They have been shown to have vasodilatory, antihypertrophic, antiaggregatory and fibrinolytic effects due to the BK B(2) receptor-mediated release of the autacoids nitric oxide, prostacyclin and tissue plasminogen activator.
Localization (release) of tissue plasminogen activator associated with bradykinin
16) Confidence 0.04 Published 2000 Journal Drug News Perspect. Section Abstract Doc Link 12937626 Disease Relevance 1.30 Pain Relevance 0.89
The following factors were thus assessed: lipid factors: cholesterol, triglycerides, high density lipoprotein cholesterol, low density lipoprotein cholesterol, apolipoprotein AI, apolipoprotein B; coagulation factors: fibrinogen, antithrombin III, fibrinopeptide A, factor VIII coagulant, factor VIII antigen, protein C; factors of physiological fibrinolysis: plasminogen, alpha 2-antiplasmin, tissue plasminogen activator and euglobulin clot lysis time before and after venous occlusion, plasminogen activator inhibitor before venous occlusion; and factors of platelet release: beta-thromboglobulin, platelet factor 4.
Localization (before) of tissue plasminogen activator in platelet associated with disorder of lipid metabolism
17) Confidence 0.01 Published 1993 Journal Int. J. Cardiol. Section Abstract Doc Link 8444504 Disease Relevance 1.03 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox